BLASTID Analysis: $104M Raised
What is BLASTID?
BLASTID leverages advanced microfluidics, novel optics, and predictive machine learning to rapidly identify and analyze individual cells, including drug-resistant pathogens. The platform enables clinicians to detect pathogens and monitor antibiotic resistance in minutes, addressing the global crisis of antimicrobial resistance. Backed by a $104M ARPA-H grant, the company's technology is designed to reduce sepsis mortality by enabling timely, effective therapy.
Location
Boston, United States
Employees
11-50
Founded
2023
Product Features & Capabilities
- Rapid pathogen detection in minutes
- Super-resolution imaging for pathogen analysis
- Predictive machine learning to identify microbial populations
- Automated antibiotic testing
- Clinical diagnostics for sepsis and drug-resistant infections
Use Cases
Detect sepsis-causing pathogens within minutes; Monitor antibiotic resistance in real-time; Identify drug-resistant bacteria in clinical samples; Enable rapid therapy decisions for sepsis patients; Screen for antimicrobial resistance in hospital settings
How much BLASTID raised
Funding - $104M
Other Considerations
Backed by $104M ARPA-H DARTS grant; Developed at Harvard Medical School; Scientific foundation from Dr. Johan Paulsson's work on AMR; Partnerships with Harvard Medical School and ARPA-H; Focus on sepsis and antimicrobial resistance crisis with 80% mortality reduction potential
See something that needs updating? Suggest edits to this profile.